WEGOVY 2.4 MG FLEXTOUCH 9.6mg/3mL
THIS IS A PRESCRIPTION MEDICINE AND SUPPLY REQUIRES A PRESCRIPTION FROM A NZ REGISTERED DOCTOR. ASK YOUR DOCTOR IF THIS MEDICINE IS RIGHT FOR YOU. ALWAYS READ THE LABEL. USE AS DIRECTED. IF SYMPTOMS PERSIST, SEE YOUR HEALTHCARE PROFESSIONAL. MEDICINES HAVE RISKS AND BENEFITS. INCORRECT USE MAY BE HARMFUL. THE PHARMACIST RESERVES THE RIGHT TO NOT SUPPLY IN LINE WITH OUR PROFESSIONAL AND LEGAL OBLIGATIONS.
Use
Prescription Only Medicine. Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management (including weight loss and weight maintenance) in adults with an initial Body Mass Index (BMI) of 30 kg/m2 or more. Adjunctive treatment for weight management in individuals with a body mass index (BMI) of 27 kg/m2 or more in the presence of at least one weight-related co-morbidity. To reduce the risk of cardiovascular events and established cardiovascular disease or multiple risk factors. Ask your doctor if Wegovy is right for you. Additional information and Consumer Medicine Information can be obtained from www.medsafe.govt.nz. Wegovy is a nonfunded medicine. Novo Nordisk Pharmaceuticals Ltd , Auckland.
TAPS Approval No: PP4508
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
THIS IS A PRESCRIPTION MEDICINE AND SUPPLY REQUIRES A PRESCRIPTION FROM A NZ REGISTERED DOCTOR. ASK YOUR DOCTOR IF THIS MEDICINE IS RIGHT FOR YOU. ALWAYS READ THE LABEL. USE AS DIRECTED. IF SYMPTOMS PERSIST, SEE YOUR HEALTHCARE PROFESSIONAL. MEDICINES HAVE RISKS AND BENEFITS. INCORRECT USE MAY BE HARMFUL. THE PHARMACIST RESERVES THE RIGHT TO NOT SUPPLY IN LINE WITH OUR PROFESSIONAL AND LEGAL OBLIGATIONS.
Use
Prescription Only Medicine. Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management (including weight loss and weight maintenance) in adults with an initial Body Mass Index (BMI) of 30 kg/m2 or more. Adjunctive treatment for weight management in individuals with a body mass index (BMI) of 27 kg/m2 or more in the presence of at least one weight-related co-morbidity. To reduce the risk of cardiovascular events and established cardiovascular disease or multiple risk factors. Ask your doctor if Wegovy is right for you. Additional information and Consumer Medicine Information can be obtained from www.medsafe.govt.nz. Wegovy is a nonfunded medicine. Novo Nordisk Pharmaceuticals Ltd , Auckland.
TAPS Approval No: PP4508
